Treatment algorithms in Crohn's - up, down or something else?

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Crohn's disease is a chronic, disabling condition requiring new therapeutic strategies.
• Mucosal healing, not just symptom control, is a crucial goal associated with better patient outcomes.
• Current therapies like thiopurines may have overestimated efficacy and underestimated risks of malignancies.

Purpose of the Study:

• To evaluate the role of mucosal healing as a therapeutic goal in Crohn's disease.
• To assess the efficacy and safety of different therapeutic classes, including anti-TNF agents, thiopurines, and methotrexate.
• To provide updated recommendations for Crohn's disease treatment strategies in 2014.

Main Methods:

• Review of recent evidence on Crohn's disease therapies.
• Analysis of treatment outcomes focusing on mucosal healing.
• Evaluation of risks associated with thiopurines, including malignancies.
• Assessment of methotrexate's potential for disease modification.

Main Results:

• Anti-tumour necrosis factor (anti-TNF) therapy is the most potent for inducing and maintaining mucosal healing.
• The efficacy of thiopurines may be overestimated, with an underestimated risk of malignancies (lymphoma, non-melanoma skin cancers, myeloid disorders).
• Methotrexate is well-tolerated, but its disease-modifying potential remains unclear.

Conclusions:

• Achieving mucosal healing, especially in early Crohn's disease, can significantly alter disease course and improve patients' lives.
• In 2014, anti-TNF therapy should be considered first-line for severe/complicated Crohn's disease or those with poor prognostic factors.
• For other patients, a rapid step-up approach with close monitoring is recommended.